Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-03-20

FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Lannett Company, Inc.)

View source ↗

Summary

The FDA approved a supplemental application from Lannett Company for a buprenorphine/naloxone product, expanding access to a generic treatment option for opioid…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Buprenorphine and naloxone (BUPRENORPHINE AND NALOXONE)

Snippet

SUPPL AP for BUPRENORPHINE AND NALOXONE (BUPRENORPHINE AND NALOXONE)